A Phase 1/2, Single-arm, Open-label Study of SGN-35 in Japanese Patients with relapsed/refractory CD30-positive Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 21 May 2016
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Anaplastic large cell lymphoma; Hodgkin's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Takeda Pharma
- 05 Nov 2015 New source identified and integrated (JapicCTI111650).
- 25 Mar 2013 Results will be presented at a future medical conference, according to a Takeda media release.
- 25 Mar 2013 Status changed from recruiting to completed, as reported in a Takeda media release.